{"entity":{"id":"minerva-prime","kind":"drug","name":"MinerVa Prime","aka":["Genecast MinerVa Prime"],"tldr":"Genecast's personalised blood test for leftover cancer, used to follow patients with EGFR-mutated lung cancer after surgery in the EVIDENCE trial.","summary":"MinerVa Prime is the personalised residual disease assay of Genecast Biotechnology of Wuxi. Its largest published use is the MRD analysis of the phase 3 EVIDENCE trial of adjuvant icotinib versus chemotherapy in resected stage II to IIIA EGFR-mutated non-small cell lung cancer (Zhou et al., Nature Communications 2026): 1,352 plasma samples from 175 patients. At the landmark it found residual disease in 35.8 per cent of stage III and 14.7 per cent of stage II patients, with a longitudinal positivity of 47.4 per cent; positivity was associated with shorter disease-free survival at the landmark (hazard ratio 4.44) and over follow-up (7.82), longitudinal negative predictive value was 91.3 per cent, and median lead time over clinical recurrence was 169 days.","status":"emerging","asOf":"2026-11-04","links":[{"label":"Zhou et al., MRD in the EVIDENCE trial (Nature Communications 2026)","url":"https://doi.org/10.1038/s41467-026-76392-9"}],"tags":["test","mrd"],"related":["brprophet"],"cancers":["nsclc"],"sections":[],"technologies":["mrd-testing","liquid-biopsy"],"targets":[],"drugs":["icotinib"],"companies":["genecast"],"institutions":[],"pathways":[],"terms":["mrd","ctdna","tumour-informed-assay"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-zhou-minerva-prime-evidence-nat-commun-2026"],"journals":[],"dependsOn":[],"notes":["Stated limit of detection, from the paper's full text: \"Probit analysis determined the limit of detection (LoD) values of 0.0075%, 0.0042%, and 0.0024% for 5 ng, 10 ng, and 30 ng inputs, respectively, when tracking 50 variants per sample\" (Zhou et al., Nature Communications 2026). That is 75, 42 and 24 parts per million.","Results are reported as tumour genome equivalents per mL with a residual disease call; no clone attribution is reported."],"brand":"MinerVa Prime","modality":"Tumour-informed ctDNA minimal residual disease test (up to 52 variants plus a hotspot panel)","mechanism":"Tumour whole-exome sequencing selects up to 52 patient-specific variants, read in plasma together with a fixed panel of more than 1,000 mutation hotspots.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/minerva-prime/","neighbours":{"drug":[{"id":"brprophet","kind":"drug","name":"brPROPHET","route":"/drugs/brprophet/"},{"id":"icotinib","kind":"drug","name":"Icotinib","route":"/drugs/icotinib/"}],"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"}],"company":[{"id":"genecast","kind":"company","name":"Genecast Biotechnology","route":"/companies/genecast/"}],"term":[{"id":"ctdna","kind":"term","name":"Circulating tumour DNA (ctDNA)","route":"/terms/ctdna/"},{"id":"mrd","kind":"term","name":"Minimal / molecular residual disease (MRD)","route":"/terms/mrd/"},{"id":"tumour-informed-assay","kind":"term","name":"Tumour-informed versus tumour-naive ctDNA assays","route":"/terms/tumour-informed-assay/"}],"paper":[{"id":"paper-zhou-minerva-prime-evidence-nat-commun-2026","kind":"paper","name":"Clinical utility of molecular residual disease detection in early-stage resected EGFR-mutated non-small cell lung cancer","route":"/key-papers/paper-zhou-minerva-prime-evidence-nat-commun-2026/"}]}}